Effect of CD38 on the multidrug resistance of human chronic myelogenous leukemia K562 cells to doxorubicin

Yalçintepe,Leman; Halis,Emre; Ulku,Sibel

doi:10.3892/ol.2016.4165

Effect of CD38 on the multidrug resistance of human chronic myelogenous leukemia K562 cells to doxorubicin

Authors:
- Leman Yalçintepe
- Emre Halis
- Sibel Ulku
View Affiliations

Affiliations: Department of Biophysics, Istanbul Faculty of Medicine, Istanbul University, Çapa‑Istanbul, Istanbul 34093, Turkey
Published online on: January 29, 2016 https://doi.org/10.3892/ol.2016.4165
Pages: 2290-2296

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance is a serious challenge in cancer chemotherapy. Alterations in the intracellular concentration and homeostasis of calcium (Ca2+) may contribute to the development of drug resistance. To investigate the mechanism of drug resistance in leukemia, the present study rendered human chronic myelogenous leukemia K562 cells resistant to the cytotoxic effect of doxorubicin by progressively adapting the sensitive parental K562 cells to doxorubicin. The resulting cells were termed K562/DOX. Subsequently, the expression of two multidrug resistance proteins, P‑glycoprotein (P‑gp) and multidrug resistance protein 1 (MRP1), was analyzed in K562/DOX cells. In addition to P‑gp and MRP1, these cells also expressed cluster of differentiation (CD)38 and its active enzyme adenosine diphosphate (ADP)‑ribosyl cyclase. The present study also demonstrated that K562/DOX cells responded to cyclic ADP‑ribose‑mediated increases in intracellular Ca2+. These data indicate that CD38 may participate in the development of drug resistance to doxorubicin in K562 cells.

View Figures

View References

1	Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N and Sarkar S: Drug Resistance in Cancer: An overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
2	Kovalev AA, Tsvetaeva DA and Grudinskaja TV: Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol. 35:287–290. 2013.PubMed/NCBI
3	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
4	Higgins CF: Multiple molecular mechanisms for multidrug resistance transporters. Nature. 446:749–757. 2007. View Article : Google Scholar : PubMed/NCBI
5	Nooter K, de la Riviere Brutel G, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JG, Stoter G and Foekens JA: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer. 76:486–493. 1997. View Article : Google Scholar : PubMed/NCBI
6	Juranka PF, Zastawny RL and Ling V: P-glycoprotein: Multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J. 3:2583–2592. 1989.PubMed/NCBI
7	Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L and Mehta K: Human CD38: A glycoprotein in search of a function. Immunol Today. 15:95–97. 1994. View Article : Google Scholar : PubMed/NCBI
8	Jackson DG and Bell JI: Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol. 144:2811–2815. 1990.PubMed/NCBI
9	Summerhill RJ, Jackson DG and Galione A: Human lymphocyte antigen CD38 catalyzes the production of cyclic ADP-ribose. FEBS Lett. 335:231–233. 1993. View Article : Google Scholar : PubMed/NCBI
10	Zocchi E, Franco L, Guida L, Benatti U, Bargellesi A, Malavasi F, Lee HC and De Flora A: A single protein immunologically identified as CD38 displays NAD⁺ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun. 196:1459–1465. 1993. View Article : Google Scholar : PubMed/NCBI
11	Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, Walseth TF and Lee HC: Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 262:1056–1059. 1993. View Article : Google Scholar : PubMed/NCBI
12	Takasawa S, Tohgo A, Noguchi N, Koguma T, Nata K, Sugimoto T, Yonekura H and Okamoto H: Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP. J Biol Chem. 268:26052–26054. 1993.PubMed/NCBI
13	Inageda K, Takahashi K, Tokita K, Nishina H, Kanaho Y, Kukimoto I, Kontani K, Hoshino S and Katada T: Enzyme properties of Aplysia ADP-ribosyl cyclase: Comparison with NAD glycohydrolase of CD38 antigen. J Biochem. 117:125–131. 1995.PubMed/NCBI
14	Galione A: Ca⁽²⁺⁾-induced Ca²⁺ release and its modulation by cyclic ADP-ribose. Trends Pharmacol Sci. 13:304–306. 1992. View Article : Google Scholar : PubMed/NCBI
15	Lee HC: Cyclic ADP-ribose: A new member of a super family of signalling cyclic nucleotides. Cell Signal. 6:591–600. 1994. View Article : Google Scholar : PubMed/NCBI
16	Aarhus R, Graeff RM, Dickey DM, Walseth TF and Lee HC: ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J Biol Chem. 270:30327–30333. 1995. View Article : Google Scholar : PubMed/NCBI
17	Lee HC: Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu Rev Pharmacol Toxicol. 41:317–345. 2001. View Article : Google Scholar : PubMed/NCBI
18	Berridge MJ, Bootman MD and Roderick HL: Calcium signalling: Dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 4:517–529. 2003. View Article : Google Scholar : PubMed/NCBI
19	Smaili SS, Pereira GJ, Costa MM, Rocha KK, Rodrigues L, do Carmo LG, Hirata H and Hsu YT: The role of calcium stores in apoptosis and autophagy. Curr Mol Med. 13:252–265. 2013. View Article : Google Scholar : PubMed/NCBI
20	Sulová Z, Seres M, Barancík M, Gibalová L, Uhrík B, Poleková L and Breier A: Does any relationship exist between P-glycoprotein-mediated multidrug resistance and intracellular calcium homeostasis. Gen Physiol Biophys. 28:F89–F95. 2009.PubMed/NCBI
21	Florea AM and Büsselberg D: Anti-cancer drugs interfere with intracellular calcium signaling. Neurotoxicology. 30:803–810. 2009. View Article : Google Scholar : PubMed/NCBI
22	Pétriz J and García-López J: Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia. 11:1124–1130. 1997. View Article : Google Scholar : PubMed/NCBI
23	Graeff RM, Walseth TF, Fryxell K, Branton WD and Lee HC: Enzymatic synthesis and characterizations of cyclic GDP-ribose. A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity. J Biol Chem. 269:30260–30267. 1994.PubMed/NCBI
24	Yalcintepe L, Albeniz I, Adin-Cinar S, Tiryaki D, Bermek E, Graeff RM and Lee HC: Nuclear CD38 in retinoic acid-induced HL-60 cells. Exp Cell Res. 303:14–21. 2005. View Article : Google Scholar : PubMed/NCBI
25	Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
26	Grynkiewicz G, Poenie M and Tsien RY: A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. J Biol Chem. 260:3440–3450. 1985.PubMed/NCBI
27	Zocchi E, Usai C, Guida L, Franco L, Bruzzone S, Passalacqua M and De Flora A: Ligand-induced internalization of CD38 results in intracellular Ca2+ mobilization: Role of NAD+ transport across cell membranes. FASEB J. 13:273–283. 1999.PubMed/NCBI
28	Watson WD, Facchina SL, Grimaldi M and Verma A: Sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) inhibitors identify a novel calcium pool in the central nervous system. J Neurochem. 87:30–43. 2003. View Article : Google Scholar : PubMed/NCBI
29	Chen JS, Agarwal N and Mehta K: Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat. 71:237–247. 2002. View Article : Google Scholar : PubMed/NCBI
30	Gutheil JC, Hart SR, Belani CP, Melera PW and Hussain A: Alterations in Ca²⁺ transport ATPase and P-glycoprotein expression can mediate resistance to thapsigargin. J Biol Chem. 269:7976–7981. 1994.PubMed/NCBI
31	Kellner U, Hutchinson L, Seidel A, Lage H, Danks MK, Dietel M and Kaufmann SH: Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int J Cancer. 71:817–824. 1997. View Article : Google Scholar : PubMed/NCBI
32	Dürig J, Naschar M, Schmücker U, Renzing-Köhler K, Hölter T, Hüttmann A and Dührsen U: CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia. 16:30–35. 2002. View Article : Google Scholar : PubMed/NCBI
33	Guse AH: Regulation of calcium signaling by the second messenger cyclic adenosine diphosphoribose (cADPR). Curr Mol Med. 4:239–248. 2004. View Article : Google Scholar : PubMed/NCBI
34	Aksoy P, Escande C, White TA, Thompson M, Soares S, Benech JC and Chini EN: Regulation of SIRT 1 mediated NAD dependent deacetylation: A novel role for the multifunctional enzyme CD38. Biochem Biophys Res Commun. 349:353–359. 2006. View Article : Google Scholar : PubMed/NCBI
35	Wang Z and Chen W: Emerging roles of SIRT1 in cancer drug resistance. Genes Cancer. 4:82–90. 2013. View Article : Google Scholar : PubMed/NCBI
36	Chu F, Chou PM, Zheng X, Mirkin BL and Rebbaa A: Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 65:10183–10187. 2005. View Article : Google Scholar : PubMed/NCBI
37	Oh WK, Cho KB, Hien TT, Kim TH, Kim HS, Dao TT, Han HK, Kwon SM, Ahn SG, Yoon JH, et al: Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol Pharmacol. 78:855–864. 2010. View Article : Google Scholar : PubMed/NCBI
38	Wang Z, Liu Z, Wu X, Chu S, Wang J, Yuan H, Roth M, Yuan YC, Bhatia R and Chen WY: ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance. PLoS Genet. 10:e10044142014. View Article : Google Scholar : PubMed/NCBI